Clinical Trials Logo

Filter by:
NCT ID: NCT01787578 Withdrawn - Clinical trials for X-Linked Adrenoleukodystrophy

Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD)

Start date: April 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, tolerance, pharmacokinetics, and pharmacodynamics of sobetirome, a selective thyroid hormone analog, in adult male X-ALD patients.

NCT ID: NCT01795170 Withdrawn - Clinical trials for Pyridoxine Dependant Epilepsy

Neurodevelopmental Outcome of Early Dietary Lysine Restriction in Pyridoxine Dependent Epilepsy Patients

NOEL
Start date: April 2013
Phase: N/A
Study type: Observational

Restricting dietary lysine intake in infants from age 3 months or less with confirmed diagnosis of pyridoxine-dependent epilepsy due to Antiquitin (ATQ) deficiency will: reduce the accumulation of neurotoxic substratesα-aminoadipicsemialdehydeandits cyclic equivalent 1-piperideine-6-carboxylate;and will improve overall neurodevelopmental outcome at 3 years of age by acting as an effective intervention into the complex pathophysiology of the condition.

NCT ID: NCT01798277 Withdrawn - Clinical trials for Coronary Artery Disease

Trial Comparing Ablation With Medical Therapy in Patients With Ventricular Tachycardia

VeTAMed
Start date: April 2013
Phase: Phase 3
Study type: Interventional

This study aims to compare antiarrhythmic drug therapy with catheter ablation using the SmartTOUCH catheter (Biosense Webster Inc.) as treatment for patients with ventricular tachycardia and coronary artery disease

NCT ID: NCT01803425 Withdrawn - Clinical trials for Immunisation Against Streptococcus Pneumoniae

Post-marketing Safety Study of GlaxoSmithKline (GSK) Biologicals' Synflorix™ Vaccine, in Healthy Infants and Children in Sri Lanka

Start date: April 2013
Phase: N/A
Study type: Observational

This PMS study aims to collect safety and reactogenicity data of Synflorix™ in healthy infants and children of the local population as per the licensing requirement of the Sri Lankan regulatory authority.

NCT ID: NCT01820091 Withdrawn - Clinical trials for Non-Small Cell Lung Cancer

Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®

Start date: April 2013
Phase: Phase 1
Study type: Interventional

To determine the optimal dose and schedule of Fusilev to prevent or reduce Folotyn-related Grade 3 or higher oral mucositis in patients with Non-Small Cell Lung Cancer.

NCT ID: NCT01820273 Withdrawn - Obesity Clinical Trials

Changes in Incretins Response and Glycemic Control After Gastric Bypass Surgery in Type 2 Diabetic Patients Versus Healthy

Start date: April 2013
Phase:
Study type: Observational

The purpose of this study is to determine the early changes in gut hormonal, and other metabolites with known relations to the glycemic homeostasis. The study mainly focus on these responses to food in the diabetic patient, compared to the non-diabetic, after gastric bypass surgery. Also aiming for recording changes in the earliest postoperative phase.

NCT ID: NCT01828125 Withdrawn - Type 1 Diabetes Clinical Trials

Efficacy of Small Subcutaneous Glucagon Dose to Treat Hypoglycemia in Adults With Type 1 Diabetes

Start date: April 2013
Phase: Phase 2
Study type: Interventional

In the unfortunate case of severe hypoglycaemia, glucagon is the first-line treatment because of its potent and rapid action starting as fast as 5 minutes after subcutaneous or intramuscular injection. Large dose of glucagon such as 1 mg subcutaneous is usually associated with undesirable side-effects such as nausea, vomiting, bloating and headache. The overall objective of this research proposal is to assess the efficacy of lower subcutaneous doses of glucagon (0.1 mg or 0.2 mg) to correct hypoglycaemia compared to the standard dose (1.0 mg) in adults with type 1 diabetes mellitus (T1D). It is postulated that much lower dosages of glucagon (0.1 or 0.2 mg) injected subcutaneously will be just as effective as the current recommended dose of 1.0 mg to correct hypoglycaemia without the undesirable gastro-intestinal side effects.

NCT ID: NCT01835106 Withdrawn - Postoperative Pain Clinical Trials

Efficacy of an Epidural Versus a Fascia Iliaca Compartment Catheter After Hip Surgery

Start date: April 2013
Phase: N/A
Study type: Interventional

The investigators are investigating two ways of treating pain after hip surgery. One way is though a thin tube (called a catheter), and it is placed into the back so that pain-numbing drugs can reach the nerves near the backbone. This is called an "epidural" catheter. Another way is to place the catheter close to the hip, where the surgery is done, so that the pain-numbing drugs can reach some of the nerves more locally. This is called a "fascia iliaca compartment" catheter. The investigators do not know which way is best to treat pain, or has fewer side effects, or allows a patient to leave hospital faster. Usually, patients would receive only one type of catheter for pain relief. To do this comparison, the investigators would place both catheter types, so that patients help us tell which one works better.

NCT ID: NCT01836341 Withdrawn - Clinical trials for Non-small Cell Lung Cancer

Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation

Start date: April 2013
Phase: Phase 1
Study type: Interventional

The purpose of this Phase I study is to test the safety of combining afatinib with standard chemotherapy and radiation. The drug afatinib will be given before the chemotherapy and radiation therapy to shrink the tumor and evaluate how afatinib affects the patient. This study will then test the safety of afatinib at different dose levels when combined with the chemotherapy drugs cisplatin or carboplatin, and pemetrexed. These treatments will be given during radiation treatment and the drug afatinib will be continued after chemotherapy and radiation.

NCT ID: NCT01841814 Withdrawn - Lymphoma Clinical Trials

Evolution of Bone Mineral Density (BMD) in Patients With Lymphoma Undergoing Chemotherapy

LYMPHOS
Start date: April 2013
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess changes of bone mineral density (BMD) at 12 months during the therapeutic management of patients with lymphoma.